$ACRS News

Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On

Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052

Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate

Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12

Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth

Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10

Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - Slideshow

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics Announces Top Line Results From Its Phase 1a Single And Multiple Ascending Dose Trial Of Its Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 And The Selection Of Lichen Llanus As The lead Indication For Its Selective ITK/JAK3 Inhibitor ATI-2138

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026

Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $10

Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming